paper
analyz
main
trend
develop
acquir
immunodefici
syndrom
aid
vaccin
recent
year
design
vaccin
provid
robust
protect
infect
remain
challeng
despit
mani
year
effort
therefor
describ
receptor
bind
domain
target
develop
aid
vaccin
recommend
measur
could
induc
effici
produc
crossreact
neutral
antibodi
high
bind
affin
measur
may
offer
new
way
research
develop
potent
broad
aid
vaccin
global
pandem
acquir
immunodefici
syndrom
aid
caus
hiv
continu
expand
still
seriou
global
health
problem
report
million
peopl
live
hiv
global
joint
unit
nation
program
hiv
aid
unaid
report
million
peopl
becam
newli
infect
million
peopl
die
year
aid
relat
caus
unfortun
effect
prevent
vaccin
world
therefor
whether
get
safe
effect
prevent
vaccin
hotspot
difficulti
field
current
intern
aid
research
far
aid
vaccin
develop
follow
three
major
trend
first
wave
candid
vaccin
design
envelop
protein
synthet
peptid
mimick
epitom
mainli
aim
induc
neutral
antibodi
nab
howev
induct
potent
broadli
crossreact
neutral
antibodi
respons
remain
major
challeng
confront
develop
hiv
vaccin
high
divers
high
glycosyl
larg
conform
chang
steric
restrict
epitop
receptor
bind
membran
fusion
process
prevent
antibodi
access
potenti
vulner
site
aidsvax
vaxgen
aid
vaccin
fail
clinic
trial
rais
question
strategi
use
viral
env
protein
induc
neutral
antibodi
respons
second
wave
candid
vaccin
design
vector
weaken
adenoviru
encod
protein
gag
pol
nef
stimul
cellular
immun
one
vaccin
candid
develop
research
merck
co
although
vaccin
could
elicit
strong
immun
respons
show
protect
anim
model
clinic
trial
step
discontinu
vaccin
provid
protect
vaccin
human
subject
even
associ
increas
risk
hiv
infect
recipi
third
wave
candid
vaccin
aim
induct
humer
cellmedi
immun
respons
heterogon
primingboost
strategi
one
repres
vaccin
combin
aidsvax
note
sanofi
pasteur
vectorbas
vaccin
alvac
result
phase
iii
clinic
trial
alvacaidsvax
show
modest
efficaci
reduct
hiv
infect
rate
compar
placebo
group
analysi
clinic
sampl
biom
research
intern
reveal
induct
antibodi
vaccin
may
contribut
protect
particip
infect
exampl
studi
order
identifi
risk
infect
two
sequenti
set
analys
plasma
specimen
shown
level
igg
antibodi
ab
specif
correl
decreas
risk
infect
level
iga
ab
reactiv
envelop
glycoprotein
correl
decreas
vaccin
efficaci
four
monoclon
antibodi
vaccin
describ
could
bind
vaccin
antigen
also
envelop
variabl
region
peptid
epitop
map
show
could
recogn
residu
lysin
k
posit
vaccin
envelop
residu
mutat
neutral
reduc
abrog
case
vaccin
variabl
region
target
antibodi
correl
increas
vaccin
efficaci
demonstr
past
broadli
neutral
antibodi
bind
glycan
variabl
region
residu
around
posit
crystal
structur
show
recogn
similar
residu
complet
differ
conform
suggest
region
may
exist
multipl
conform
promis
result
encourag
research
refocu
studi
structur
function
antigen
immunogen
order
identifi
critic
function
region
contain
rel
conserv
neutral
epitop
may
induc
potent
broadli
crossreact
neutral
antibodi
previou
studi
attempt
use
receptor
bind
site
rbd
viru
merscov
sar
avian
influenza
viru
model
antigen
vaccin
design
practic
strategi
achiev
good
result
induc
high
titer
neutral
antibodi
provid
effect
protect
anim
attack
viru
anim
experi
time
fulllength
viru
envelop
protein
immunogen
may
caus
immun
system
overreact
lead
neg
effect
aggrav
ill
thu
shorter
rbd
area
effect
avoid
problem
sar
vaccin
strategi
may
also
suitabl
hiv
vaccin
design
especi
find
hiv
rbd
neutral
antibodi
conserv
area
rbd
confirm
play
import
role
process
viru
infect
induc
highli
effect
broad
spectrum
neutral
antibodi
therefor
conserv
area
rbd
still
import
target
vaccin
clinic
trial
also
suggest
level
igg
specif
env
invers
correl
vaccin
protect
effect
thu
may
area
could
increas
infect
fulllength
env
shorter
rbd
may
reduc
effect
cours
differ
rbd
hiv
merscov
sar
influenza
make
much
harder
design
vaccin
base
strategi
review
focu
characterist
hiv
rbd
analyz
rbd
target
develop
hiv
vaccin
propos
new
idea
new
specificboost
strategi
base
issu
provid
new
thought
research
develop
effect
aid
vaccin
like
viral
envelop
glycoprotein
hiv
env
consist
two
subunit
surfac
glycoprotein
su
respons
bind
receptor
molecul
transmembran
glycoprotein
tm
mediat
fusion
viral
membran
cell
membran
figur
entri
hiv
target
cell
initi
bind
viral
envelop
spike
protein
env
surfac
subunit
primari
receptor
via
bind
site
result
exposur
coreceptor
bind
domain
conform
bind
coreceptor
caus
seri
conform
chang
env
transmembran
subunit
lead
fusion
viral
envelop
target
cell
membran
therefor
play
import
role
viral
bind
receptor
coreceptor
well
entri
target
cell
rbd
may
serv
attract
target
aid
vaccin
develop
consist
five
conserv
region
interspac
five
variabl
region
region
creat
surfaceexpos
loop
anchor
disulfid
bond
base
third
variabl
loop
separ
main
bodi
direct
contact
coreceptor
viral
fusion
make
key
determin
defin
coreceptor
select
crystallograph
analys
structur
truncat
siv
free
complex
andor
neutral
antibodi
indic
conform
monom
compris
inner
domain
outer
domain
link
bridg
sheet
figur
b
show
core
compris
helic
defin
loop
segment
outer
domain
consist
sixstrand
mixeddirect
sheet
clamp
helic
sevenstrand
antiparallel
barrel
structur
conserv
caviti
local
inner
outer
domain
target
cell
protrud
interact
viral
cellular
receptor
differ
sar
influenza
hiv
stronger
conform
locat
multipl
area
discontinu
determin
consist
residu
caviti
includ
addit
sever
residu
outsid
caviti
coreceptor
bind
site
locat
bridg
sheet
form
structur
rearrang
induc
upon
bind
furthermor
conform
chang
variabl
domain
allow
loop
bind
coreceptor
mainli
second
extracellular
loop
critic
role
rbd
viral
bind
thought
ideal
target
elicit
broadli
crossreact
neutral
antibodi
first
human
monoclon
antibodi
mab
identifi
burton
colleagu
bind
via
compet
solubl
bind
strongli
neutral
broad
spectrum
cell
deriv
laboratori
tcla
strain
primari
isol
recent
sever
potent
neutral
mab
includ
identifi
differ
group
mab
neutral
differ
hiv
clade
test
pvl
antibodi
deriv
germlin
allel
target
conserv
bind
site
avail
structur
inform
show
antibodi
within
hydrogen
bond
distanc
respect
hydrogen
bond
crystal
structur
sever
ab
bound
reveal
molecular
detail
neutral
mechan
facilit
structurebas
ration
design
improv
potenc
breadth
find
surpris
subsequ
discoveri
antibodi
differ
seroposit
human
donor
arous
enthusiasm
peopl
vaccin
target
spotlight
result
markedli
promot
interest
studi
neutral
antibodi
design
immunogen
elicit
nab
interestingli
mab
neutral
activ
neutral
tcla
strain
depend
bind
affin
trimer
mab
similar
bind
affin
monom
trimer
surfac
infect
cell
mab
neutral
activ
weaker
affin
trimer
suggest
mab
without
strong
neutral
activ
recogn
access
nativ
conform
epitop
although
breadth
neutral
somewhat
limit
either
variat
sequenc
bind
loop
distal
mutat
seem
affect
access
epitop
nativ
env
trimer
therefor
design
aid
vaccin
essenti
maintain
conform
neutral
epitop
nativ
trimer
group
aim
construct
trimer
nativ
conform
link
extracellular
region
coval
fuse
trimer
domain
express
solubl
oligom
group
express
uncleav
unactiv
use
fold
trimer
domain
phage
pilu
packag
nativ
cytoplasm
domain
delet
use
protein
liposom
unfortun
howev
neutral
epitop
trimer
show
weak
immunogen
probabl
trimer
recess
pocket
make
hard
antibodi
access
meanwhil
nonneutr
epitop
strong
immunogen
observ
weaken
immun
system
produc
antibodi
neutral
epitop
therefor
enhanc
immunogen
neutral
epitop
suppress
immunogen
nonneutr
epitop
import
approach
design
vaccin
instanc
antigen
immunogen
immunodomin
nonneutr
epitop
abrog
sever
way
includ
induct
conform
chang
mutat
glycan
shield
carbohydr
molecul
recent
human
bind
site
monoclon
antibodi
separ
immort
peripher
blood
lymphocyt
blood
posit
volunt
report
although
epitop
describ
current
studi
import
note
recent
prove
induc
shed
spike
primari
also
mediat
shed
effect
share
function
properti
lack
may
attribut
partli
conform
chang
bind
spike
seem
common
weak
neutral
broad
sensit
mutat
perspect
differ
way
posit
antibodi
crucial
recogn
effect
consid
antibodi
fab
arm
twice
width
henc
studi
show
posit
play
import
role
antibodi
effect
recognit
avail
evid
suggest
biolog
import
coreceptor
hiv
chemokin
receptor
consist
extracellular
nterminu
intracellular
cterminu
seven
helic
transmembran
domain
sever
conserv
pro
residu
three
intracellular
extracellular
loop
compos
hydrophil
amino
acid
hydrophil
charg
residu
interact
polar
face
hydrogen
bond
ring
hydroxyl
group
thu
base
hydrophil
amino
acid
design
peptid
contain
polar
group
interact
hydrophil
amino
acid
nterminu
contain
sever
sulfat
tyrosin
play
critic
role
associ
viral
entri
studi
show
play
critic
role
interact
sulfat
human
mab
interact
site
mention
bind
induc
format
bridg
sheet
exposur
coreceptor
bind
site
includ
loop
region
conserv
epitop
bridg
sheet
contain
neutral
epitop
elicit
broadli
crossreact
neutral
antibodi
number
experiment
find
confirm
exist
epitop
first
affin
solubl
coreceptor
could
greatli
enhanc
bind
second
solubl
could
markedli
enhanc
fusion
effici
cell
express
coreceptor
third
bind
could
enhanc
affin
human
mab
bind
sever
group
mimick
conform
epitop
induc
nab
howev
nab
rel
conserv
structur
loop
interact
succeed
exhibit
broadli
crossreact
neutral
activ
quaternari
site
includ
variabl
loop
glycosyl
site
neutral
antibodi
bind
variabl
loop
identifi
target
site
loop
interact
loop
figur
pgt
reli
primarili
backbon
interact
respect
form
main
chain
strand
associ
substanti
proport
broadli
neutral
antibodi
bnab
identifi
certain
infect
donor
recogn
glycandepend
epitop
bind
glycosyl
site
neutral
antibodi
like
monoclon
antibodi
determin
found
bind
dual
glycan
scaffold
glycopeptid
highmannos
glycan
respect
number
glycandepend
bnab
includ
pgt
pgt
pgt
appear
new
singlecel
clone
techniqu
hope
bnab
greatli
expand
includ
number
quaternari
specif
ab
includ
glycosyl
antigen
variabl
cycl
neutral
antibodi
need
access
fragil
site
coat
trimer
aid
viru
howev
complic
quaternari
structur
trimer
envelop
spike
effici
protect
function
import
domain
research
analys
broadli
neutral
antibodi
crystal
structur
found
interact
van
der
waal
hydrogen
bond
salt
bridg
therefor
use
method
modifi
antibodi
improv
interact
gain
effect
neutral
antibodi
time
expect
antibodi
induc
vaccin
act
alloster
effect
bind
differ
site
variabl
loop
impli
may
play
signific
role
diseas
wide
accept
nonneutr
antibodi
nonnab
well
neutral
antibodi
nab
display
inhibitori
activ
replic
vitro
base
differ
mechan
thai
phase
iii
trial
reduc
risk
infect
vaccin
individu
correl
serum
neutral
activ
high
concentr
nonnab
provid
addit
support
possibl
contribut
nonnab
function
protect
thu
conclud
nonneutr
antibodi
may
also
effect
prevent
infect
recent
number
antibodi
includ
recogn
highli
conserv
epitop
report
overlap
variou
extent
coreceptor
bind
site
tabl
epitop
known
determin
structur
complex
fab
fab
find
suggest
epitop
also
serv
target
develop
aid
vaccin
antibodi
target
nhr
pocket
transmembran
glycoprotein
figur
anchor
viral
envelop
underli
viru
particl
antibodi
target
outer
envelop
protein
studi
show
bind
envelop
glycan
wherea
block
bind
site
main
receptor
hiv
surfac
immun
cell
howev
coreceptor
bind
epitop
virion
natur
infect
process
unlik
elicit
immun
respons
base
steric
hindranc
time
limit
exposur
epitop
coreceptor
immun
system
limit
therefor
design
immunogen
contain
epitop
stabli
maintain
nativ
conform
critic
develop
coreceptor
bind
sitebas
aid
vaccin
previou
studi
demonstr
rbd
spike
protein
sever
acut
respiratori
syndrom
sar
associ
coronaviru
sarscov
one
import
target
develop
sar
vaccin
similarli
rbd
includ
also
attract
target
develop
aid
vaccin
recent
identif
sever
seri
human
broadli
crossreact
neutral
antibodi
target
epitop
howev
unlik
rbd
sarscov
spike
protein
consist
short
fragment
amino
acid
residu
coreceptor
bind
domain
form
number
amino
acid
discontinu
spread
almost
entir
molecul
complic
design
aid
vaccin
contain
andor
epitop
maintain
nativ
conform
transitori
exposur
epitop
presenc
nonneutr
immunodomin
epitop
addit
obstacl
therefor
design
vaccin
abil
induc
highli
potent
crossreact
neutral
antibodi
high
bind
affin
recommend
follow
strategi
construct
immunogen
contain
discontinu
sequenc
andor
epitop
natur
trimer
conform
essenti
induc
conform
chang
mutat
glycan
shield
nonneutr
immunodomin
epitop
immunogen
order
reduc
immunogen
epitop
add
immun
potenti
motif
immunogen
order
enhanc
immunogen
rbd
base
vaccin
base
strategi
propos
new
strategyspecificboost
strategi
core
new
strategi
inspir
specif
neutral
antibodi
rbd
epitop
base
natur
env
trimer
use
primingboost
mode
use
plasmid
express
natur
trimer
env
protein
alvac
vector
vlp
particl
immun
first
arous
activ
immun
cell
natur
trimer
env
rbd
immun
system
cours
part
immun
cell
may
account
small
part
activ
cell
use
hiv
rbd
immunogen
mutat
glycan
shield
nonneutr
immunodomin
epitop
boost
increas
specif
previous
activ
immun
cell
relat
neutral
antibodi
rbd
epitop
engin
call
use
obtain
mab
good
antigen
candid
boost
shape
via
mutat
made
instead
bind
great
major
nonneutr
antibodi
bound
addit
also
connect
immuneenhanc
igg
fc
fragment
order
enhanc
immunogen
rbd
epitop
hope
new
strategi
provid
new
idea
aid
vaccin
research
develop
aid
vaccin
could
also
design
induc
combin
antibodi
target
differ
site
confer
breadth
potenc
protect
